Literature DB >> 16282453

Envelope is a major viral determinant of the distinct in vitro cellular transformation tropism of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2.

Li Xie1, Patrick L Green.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 are related deltaretroviruses but are distinct in their disease-inducing capacity. These viruses can infect a variety of cell types, but only T lymphocytes become transformed, which is defined in vitro as showing indefinite interleukin-2-independent growth. Studies have indicated that HTLV-1 has a preferential tropism for CD4+ T cells in vivo and is associated with the development of leukemia and neurological disease. Conversely, the in vivo T-cell tropism of HTLV-2 is less clear, although it appears that CD8+ T cells preferentially harbor the provirus, with only a few cases of disease association. The difference in T-cell transformation tropism has been confirmed in vitro as shown by the preferential transformation of CD4+ T cells by HTLV-1 versus the transformation of CD8+ T cells by HTLV-2. Our previous studies showed that Tax and overlapping Rex do not confer the distinct T-cell transformation tropisms between HTLV-1 and HTLV-2. Therefore, for this study HTLV-1 and HTLV-2 recombinants were generated to assess the contribution of LTR and env sequences in T-cell transformation tropism. Both sets of proviral recombinants expressed p19 Gag following transfection into cells. Furthermore, recombinant viruses were replication competent and had the capacity to transform T lymphocytes. Our data showed that exchange of the env gene resulted in altered T-cell transformation tropism compared to wild-type virus, while exchange of long terminal repeat sequences had no significant effect. HTLV-2/Env1 preferentially transformed CD4+ T cells similarly to wild-type HTLV-1 (wtHTLV-1), whereas HTLV-1/Env2 had a transformation tropism similar to that of wtHTLV-2 (CD8+ T cells). These results indicate that env is a major viral determinant for HTLV T-cell transformation tropism in vitro and provides strong evidence implicating its contribution to the distinct pathogenesis resulting from HTLV-1 versus HTLV-2 infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282453      PMCID: PMC1287554          DOI: 10.1128/JVI.79.23.14536-14545.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

Review 1.  Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides.

Authors:  M D Lairmore; R B Lal; P T Kaumaya
Journal:  Biomed Pept Proteins Nucleic Acids       Date:  1995

Review 2.  The HTLV-I Tax oncoprotein: hyper-tasking at the molecular level.

Authors:  Diane R Wycuff; Susan J Marriott
Journal:  Front Biosci       Date:  2005-01-01

3.  Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion.

Authors:  Ayse Kubra Coskun; Richard E Sutton
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Roles of the Ras-MEK-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt-mTOR pathways in Jaagsiekte sheep retrovirus-induced transformation of rodent fibroblast and epithelial cell lines.

Authors:  Naoyoshi Maeda; Wuxia Fu; Aurora Ortin; Marcelo de las Heras; Hung Fan
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Cholesterol dependence of HTLV-I infection.

Authors:  Matthew M Wielgosz; Daniel A Rauch; Kathryn S Jones; Frank W Ruscetti; Lee Ratner
Journal:  AIDS Res Hum Retroviruses       Date:  2005-01       Impact factor: 2.205

6.  Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone.

Authors:  M D Robek; L Ratner
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Identification of a domain within the human T-cell leukemia virus type 2 envelope required for syncytium induction and replication.

Authors:  B Poon; I S Chen
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Human T-cell leukaemia/lymphoma virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7.

Authors:  S Daenke; S A McCracken; S Booth
Journal:  J Gen Virol       Date:  1999-06       Impact factor: 3.891

9.  71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1.

Authors:  Y Sagara; C Ishida; Y Inoue; H Shiraki; Y Maeda
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Authors:  N D Collins; G C Newbound; B Albrecht; J L Beard; L Ratner; M D Lairmore
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

View more
  24 in total

1.  Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Authors:  Priya Kannian; Han Yin; Rami Doueiri; Michael D Lairmore; Soledad Fernandez; Patrick L Green
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 2.  Gene therapy works in animal models of rheumatoid arthritis...so what!

Authors:  Fons A J van de Loo; Jeroen Geurts; Wim B van den Berg
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

3.  Detection and quantitation of HTLV-1 and HTLV-2 mRNA species by real-time RT-PCR.

Authors:  Min Li; Patrick L Green
Journal:  J Virol Methods       Date:  2007-03-06       Impact factor: 2.014

4.  Human T cell leukemia virus type 2 (HTLV-2) Tax2 has a dominant activity over HTLV-1 Tax1 to immortalize human CD4+ T cells.

Authors:  Michitaka Imai; Masaya Higuchi; Hiroki Kawamura; Manami Yoshita; Masahiko Takahashi; Masayasu Oie; Hideaki Matsuki; Yuetsu Tanaka; Yutaka Aoyagi; Masahiro Fujii
Journal:  Virus Genes       Date:  2012-09-29       Impact factor: 2.332

5.  Human T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for in vitro immortalization but functions to repress early virus replication in vivo.

Authors:  Han Yin; Priya Kannian; Nathan Dissinger; Robyn Haines; Stefan Niewiesk; Patrick L Green
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

6.  Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells.

Authors:  Kathryn S Jones; Kazunori Fugo; Cari Petrow-Sadowski; Ying Huang; Daniel C Bertolette; Ivonne Lisinski; Samuel W Cushman; Steven Jacobson; Francis W Ruscetti
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner.

Authors:  Louise Dubuisson; Florence Lormières; Stefania Fochi; Jocelyn Turpin; Amandine Pasquier; Estelle Douceron; Anaïs Oliva; Ali Bazarbachi; Valérie Lallemand-Breitenbach; Hugues De Thé; Chloé Journo; Renaud Mahieux
Journal:  Oncogene       Date:  2018-03-06       Impact factor: 9.867

8.  Predicting the future: adult T-cell leukemia.

Authors:  Lee Ratner
Journal:  Blood       Date:  2020-06-04       Impact factor: 22.113

9.  Human T-cell leukemia virus type 2 Rex carboxy terminus is an inhibitory/stability domain that regulates Rex functional activity and viral replication.

Authors:  Li Xie; Matthew Kesic; Brenda Yamamoto; Min Li; Ihab Younis; Michael D Lairmore; Patrick L Green
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Authors:  Kathryn S Jones; Ying K Huang; Sébastien A Chevalier; Philippe V Afonso; Cari Petrow-Sadowski; Daniel C Bertolette; Antoine Gessain; Francis W Ruscetti; Renaud Mahieux
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.